Mei pharma, inc. (MEIP)
CashFlow / Yearly
Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11
Net (loss) income

-

-

-

-

-32,694

-27,148

-11,186

-7,523

-

Cash flows from operating activities:
Net loss

-16,819

-40,068

2,670

-20,862

-

-

-

-

-6,781

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability

27,632

-9,705

-

-

-

-

-

-

-

Financing costs associated with warrants

-

2,367

-

-

-

-

-

-

-

Share-based compensation

6,562

3,217

2,304

2,723

4,223

4,747

1,506

511

484

Fair value of derivative liabilities in excess of proceeds

-

-

-

-

-

-

-

-

-508

Gain on adjustment to fair value of derivatives

-

-

-

-

-

-

-

1,139

49

Financing costs

-

-

-

-

-

-

-

406

-

Depreciation and amortization

80

53

85

58

64

50

45

13

-

Changes in operating assets and liabilities:
Depreciation

-

-

-

-

-

-

-

-

13

Prepaid expenses and other current assets

849

-172

927

329

5

41

310

-126

170

Accounts payable

1,144

3,058

-494

216

-845

1,171

-57

266

-201

Accrued liabilities

1,105

669

-1,148

337

1,188

1,770

-42

259

-4

Deferred revenue

6,986

-208

996

-

-

-

-

-

-

Amounts due to related party

-

-

-

-

-

-

-

-

-301

Net cash used in operating activities

-29,423

-21,035

3,486

-17,857

-

-

-

-

-6,501

Cash flows from investing activities:
Net cash (used in) provided by operating activities

-

-

-

-

-28,069

-19,451

-10,044

-7,081

-

Purchases of property and equipment

217

-

51

4

15

50

38

-

48

Purchases of short-term investments

64,655

114,233

60,123

55,238

70,077

69,997

-

-

-

Proceeds from maturity of short-term investments

89,190

69,906

50,097

65,214

60,036

34,981

-

-

-

Net cash (used in) provided by investing activities

24,318

-44,327

-10,077

9,972

-

-

-

-

-48

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-10,056

-35,066

-38

-

-

Proceeds from exercise of stock options

372

329

-

-

-

-

-

-

-

Proceeds from exercise of warrants

1,118

-

-

-

-

-

-

-

-

Issuance of common stock

220

70,151

4,212

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

43,070

32,721

39,453

9,831

711

Payment of RSU tax withholdings in exchange for

324

267

-

-

-

-

-

-

-

Net proceeds from issuance of preferred stock

-

-

-

-

-

-

-

-

665

Financing costs

-

-

-

-

-

-

-

406

-

Net cash provided by financing activities

-

-

-

-

43,070

32,721

39,453

9,425

-

Net cash provided by financing activities

1,386

70,213

4,212

-

-

-

-

-

1,376

Net (decrease) increase in cash and cash equivalents

-3,719

4,851

-2,379

-7,885

4,945

-21,796

29,371

2,344

-5,173

Supplemental cash flow information:
Income taxes paid

-1

-1

-1

-1

-1

-1

-1

-1

-1

Non-cash financing activities:
Issuance of common stock for purchase of intangible assets

-

-

-

-

-

-

500

-

-